Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of UGN-104 for low-grade upper tract urothelial cancer
MOH_2025-05-07_014075Phase 3Not yet recruiting
- Sponsor
- UroGen Pharma
- Start
- May 2025
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Mitomycin C RTGel in upper tract urothelial carcinoma (UTUC), sponsored by UroGen Pharma. Planned start May 2025; status: not yet recruiting.
02
Drugs
Mitomycin C RTGel
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on MOH_2025-05-07_014075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-07_014075.